Assandri, A. published the artcileMetabolic pathways of the antihypertensive agent, N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride. I. Studies in the rat, Quality Control of 17259-32-4, the main research area is MDL 899 metabolism; pyrrolylpyridazinamine metabolism.
The metabolic fate of a new antihypertensive, MDL 899 (I) [86703-02-8] was studied in rats after both oral and i.v. administration (1 mg/kg). The compound underwent rapid metabolism, disappearing from the central compartment with a half-life of about 0.5 h. Plasma concentration of the parent drug and its major metabolite II [100499-32-9] following i.v. and oral administration suggest a route-dependent first-pass metabolism Ten metabolites were isolated from the urine and identified by u.v., i.r., mass and 1H NMR spectroscopy. The structure of some was confirmed by 13C NMR and chem. synthesis. All biotransformations are restricted to the pyrrole ring which undergoes oxidative cleavage followed by a series of chem. rearrangements. A minor pathway leads to the formation of Me sulphinyl and Me sulfonyl pyrroles. It is suggested that, as with natural indoles, the pyrrole might be oxidized by a 2,3-dioxygenase. All metabolites tested (3 major and 2 minor) failed to showed antihypertensive activity in spontaneously hypertensive rats.
Xenobiotica published new progress about MDL 899 metabolism; pyrrolylpyridazinamine metabolism. 17259-32-4 belongs to class pyridazine, name is 4-(6-Chloropyridazin-3-yl)morpholine, and the molecular formula is C8H10ClN3O, Quality Control of 17259-32-4.
Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem